Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 8/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.51 |
| ▸ | HTR3B | O95264 | 2/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143426 | 0.86 | ALDH1A1 (0.45) | ADRB1CHRNB2CHRNA4HTT | |
| SCHEMBL29249307 | 0.85 | ALDH1A1 (0.44) | ADRB1CHRNB2CHRNA4HTT | |
| SCHEMBL3140130 | 0.85 | ALDH1A1 (0.44) | ADRB1CHRNB2CHRNA4TP53THRB | |
| SCHEMBL4165953 | 0.82 | ADRA2C (0.45) | HTR3AACVR1TGFBR1HTTHTR6 | |
| SCHEMBL3140169 | 0.81 | TGFBR1 (0.43) | ACVR1TGFBR1TP53CYP1A2CYP3A4 | |
| SCHEMBL16993793 | 0.78 | CHRNA7 (0.47) | THRB | |
| SCHEMBL17293924 | 0.78 | ADRB1 (0.56) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL12466108 | 0.77 | SUV39H2 (0.41) | SIGMAR1ACVR1CYP2D6 | |
| SCHEMBL12466365 | 0.77 | L3MBTL3 (0.56) | — | |
| SCHEMBL3139272 | 0.76 | ACVR1B (0.46) | ACVR1TGFBR1ACVR1BTP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | ADRB1 922/4885HTR3E 1458/4885HTR3B 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.